84.81 
1.62(1.87%) 11:37AM EDT
| Prev Close: | 84.81 |
|---|
| Open: | 84.20 |
|---|
| Bid: | 84.81 |
|---|
| Ask: | 84.83 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 84.00 - 85.05 |
|---|
| 52wk Range: | 18.50 - 85.05 |
|---|
| Volume: | 3,360,072 |
|---|
| Avg Vol (3m): | 11,960 |
|---|
| Market Cap: | 112.24B |
|---|
| P/E (ttm): | 27.06 |
|---|
| EPS (ttm): | 3.13 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in EUR.
Headlines
- Merck Insomnia Drug Safe Only in Lower Doses, Panel Saysat Bloomberg(Thu 4:34PM EDT)
- Pfizer takes its shot at a vaccine for evasive superbugReuters(Thu 1:28AM EDT)
- Merck's insomnia drug moves a step closer to U.S. approvalat Reuters(Wed, May 22)
- FDA panel says Merck's sleep drug safe, effective at lower doseat Reuters(Wed, May 22)
- FDA panel: Merck's insomnia drug effective, safe at low dosesat Reuters(Wed, May 22)
- Thrifty Merrimack developing new cancer drugs at lower costat Reuters(Wed, May 22)
- New Flu Vaccine Beats Current Products in Animal Testingat Bloomberg(Wed, May 22)
- Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Failat Bloomberg(Wed, May 22)
- French and Benelux stocks-Factors to watch on May 22at Reuters(Wed, May 22)
- Regeneron, Sanofi asthma drug seen as potential game changerat Reuters(Tue, May 21)
- Sanofi Relies on Axway to Future-Proof their Infrastructure and Reduce Operational Costs through Global ConsolidationBusiness Wire(Tue, May 21)
- Sanofi, Roll Global, Heineken, WWE: Intellectual Propertyat Bloomberg(Tue, May 21)
- Regeneron settles all pending litigation with Roche's Genentechat Reuters(Mon, May 20)
- Merck Insomnia Drug Safer at Lower Dose, FDA Staff Saysat Bloomberg(Mon, May 20)
- FDA staff says Merck's sleep drug effective, questions dosageat Reuters(Mon, May 20)
Reports
- No Reports available for SAN.PA at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 3.19 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments.
View More